Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Hanmi Says Sanofi Made 'Optimal' Efpeglenatide Decision, Still Eyes 2021 Approval

Dec 12 2019

• By Jung Won Shin

Diabetes — Hanmi And Sanofi's License Pact Still Intact • Source: Shutterstock

Related Content

Novo Anticipates Q4 Soft Launch For Closely Watched Oral GLP-1 Agent Rybelsus In The US

Sep 21 2019

Sanofi, Long-Time Leader In Diabetes, Is Exiting Diabetes Research

Dec 10 2019

Deal Watch: Sanofi Begins 2017 By Ending Vaccine JV, Completing Swap With Boehringer

Jan 03 2017

Related Companies

Sanofi

Hanmi Pharmaceutical Co., Ltd.

Eli Lilly and Company

Novo Nordisk A/S

Johnson & Johnson

Additional Topics

South Korea Asia Pacific United States Deals Commercial Metabolic Disorders BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window